V

Voyager Therapeutics
D

VYGR

5.42000
USD
0.05
(0.93%)
Market Closed
Volume
0
EPS
-1
Div Yield
-
P/E
20
Market Cap
295,570,237
OverviewSignalsIdeasNews
Related Instruments
    A
    ALKS
    -0.150
    (-0.53%)
    28.200 USD
    A
    ARCT
    -2.310
    (-12.60%)
    16.020 USD
    B
    BLUE
    -0.04270
    (-11.74%)
    0.32090 USD
    C
    CLLS
    -0.02000
    (-1.06%)
    1.87000 USD
    C
    CRSP
    0.360
    (0.77%)
    47.280 USD
    E
    EDIT
    -0.11500
    (-4.14%)
    2.66500 USD
    N
    NTLA
    -1.165
    (-7.71%)
    13.955 USD
    Q
    QURE
    -0.55000
    (-8.14%)
    6.21000 USD
    S
    SGMO
    -0.10000
    (-4.67%)
    2.04000 USD
    More
News

Title: Voyager Therapeutics

Sector: Healthcare
Industry: Biotechnology
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.